Back to Search Start Over

Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review

Authors :
K. Umezawa
Sh. Kh. Gantsev
Sh. R. Kzyrgalin
R. S. Yamidanov
R. A. Amirov
E. I. Zhuk
Source :
Креативная хирургия и онкология, Vol 11, Iss 1, Pp 68-75 (2021)
Publication Year :
2021
Publisher :
Bashkir State Medical University, 2021.

Abstract

Carcinogenesis research uncovers new pathogenesis links as vulnerable targets of effective antitumour therapies. Among the key mediators of immune response, cell proliferation, cell apoptosis and inflammation is transcription factor NF-κB. Misregulation of an NF-κB-dependent pathway is found in solid and haematopoietic tumour cells. One of the best known NF-κB functions is expression regulation of genes involved in the apoptosis inhibition or activation and survival in both intact and malignant cells. The NF-κB-mediated pathways’ involvement in carcinogenesis, angiogenesis and tumour resistance to chemo- and radiotherapies makes this factor a promising target for drug anti-cancer interventions. This review summarises evidence on the antitumour and anti-inflammatory activity of a high-potent and specific low molecular-weight NF-κB inhibitor, dehydroxymethylhepoxyquinomycin (DHMEQ), as a candidate therapeutic agent in treatment for variant malignancies.

Details

Language :
English, Russian
ISSN :
23070501 and 20763093
Volume :
11
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Креативная хирургия и онкология
Publication Type :
Academic Journal
Accession number :
edsdoj.225ac206c74c6687b51d44d931fa18
Document Type :
article
Full Text :
https://doi.org/10.24060/2076-3093-2021-11-1-68-75